Teva Pharmaceutical Industries (TEVA) Asset Writedowns and Impairment (2009 - 2024)

Teva Pharmaceutical Industries (TEVA) has reported Asset Writedowns and Impairment for 16 consecutive years, with $679.0 million the latest figure, recorded in Q1 2024.

• Quarterly Asset Writedowns and Impairment rose 259.26% year-over-year to $679.0 million in Q1 2024, while the trailing twelve-month figure through Mar 2024 was $1.6 billion (down 36.53% YoY) and the FY2023 annual result came in at $1.1 billion, down 55.95% from the prior year.
• Asset Writedowns and Impairment advanced to $679.0 million in Q1 2024 per TEVA's latest filing, from $68.0 million in the prior quarter.
• Over the last five years, Asset Writedowns and Impairment for TEVA reached as high as $5.2 billion in Q3 2020 and fell as low as $28.0 million in Q3 2022.
• A 5-year average of $666.8 million and a median of $227.0 million in 2021 frame the typical range for Asset Writedowns and Impairment.
• Annual changes were most pronounced in 2020 — Asset Writedowns and Impairment jumped 2433.66% — and 2021, when it sank 99.1%.
• Year by year, Asset Writedowns and Impairment stood at $232.0 million in 2020, then declined by 21.12% to $183.0 million in 2021, then surged by 689.62% to $1.4 billion in 2022, then slumped by 95.29% to $68.0 million in 2023, then soared by 898.53% to $679.0 million in 2024.
• According to Business Quant data, Asset Writedowns and Impairment over the past three periods registered $679.0 million, $68.0 million, and $48.0 million for Q1 2024, Q4 2023, and Q3 2023 respectively.